Antibody-RNA Conjugates represent a significant advancement in the treatment of challenging and rare diseases with unmet medical need.

Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...

South Korea’s two leading biopharmaceutical companies, Samsung Biologics and Celltrion, unveiled ambitious plans to enter the ...

HLB announced on the 14th that the last hurdle for U.S. Food and Drug Administration (FDA) approval of its liver cancer new drug, the manufacturing and quality control (CMC) audit, has been completed.

Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic ...

NextCure, Inc. has announced that it has dosed its first patient in a Phase 1 clinical trial for LNCB74, an antibody-drug conjugate targeting B7-H4 for the treatment of multiple cancers.

--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) ...

a novel tri-specific antibody, DB007, against undisclosed cancer targets. Bora will support chemistry, manufacturing, and controls (CMC) strategy through to clinical development from its 48,400-sq.-ft ...

According to latest analysis by Report Ocean, the global antibody drugs market is poised to grow by USD 91 billion during 2022-2028, progressing at a CAGR of 9.7% during the forecast period. The ...

a novel DLL3-targeted antibody drug conjugate (ADC) candidate. IBI3009 has already obtained IND approvals in Australia, China, and the U.S., with the first patient for the Phase 1 study dosed in ...

Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences had a busy end to the year, sharing news of agreements for antibody-drug conjugates (ADCs) and other assets in the final few days of ...